基于 SEMG 技术分析岐黄针结合镜像疗法对脑梗死患者上肢运动功能的影响

注册号:

Registration number:

ITMCTR2024000577

最近更新日期:

Date of Last Refreshed on:

2024-10-19

注册时间:

Date of Registration:

2024-10-19

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

基于 SEMG 技术分析岐黄针结合镜像疗法对脑梗死患者上肢运动功能的影响

Public title:

The Effect of Qihuang Needle Therapy Combined with Mirror Therapy on Upper Limb Motor Function in Patients with Cerebral Infarction: An Evaluation Based on Surface Electromyography

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于sEMG技术分析岐黄针结合镜像疗法对脑梗死患者上肢运动功能的影响

Scientific title:

The Effect of Qihuang Needle Therapy Combined with Mirror Therapy on Upper Limb Motor Function in Patients with Cerebral Infarction: An Evaluation Based on Surface Electromyography

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

崔韶阳

研究负责人:

崔韶阳

Applicant:

Cui Shaoyang

Study leader:

Cui Shaoyang

申请注册联系人电话:

Applicant telephone:

0755-83548662

研究负责人电话:

Study leader's telephone:

0755-83548662

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

herb107@126.com

研究负责人电子邮件:

Study leader's E-mail:

herb107@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

广东省深圳市福田区北环大道6001号广州中医药大学深圳医院住院楼3楼

研究负责人通讯地址:

广东省深圳市福田区北环大道6001号广州中医药大学深圳医院住院楼3楼

Applicant address:

Shenzhen Hospital (futian) of Guangzhou University of Chinese Medicine Shenzhen China

Study leader's address:

Shenzhen Hospital (futian) of Guangzhou University of Chinese Medicine ShenzhenChina

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广州中医药大学深圳医院(福田)

Applicant's institution:

Shenzhen Hospital (futian) of Guangzhou University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

GZYLL(KY)-2022-031-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

广州中医药大学深圳医院(福田)伦理委员会

Name of the ethic committee:

Shenzhen Hospital (futian) of Guangzhou University of Chinese Medicine Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2022/11/23 0:00:00

伦理委员会联系人:

卢琳

Contact Name of the ethic committee:

Lu Lin

伦理委员会联系地址:

广东省深圳市福田区北环大道6001号广州中医药大学深圳医院

Contact Address of the ethic committee:

Shenzhen Hospital (futian) of Guangzhou University of Chinese Medicine

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 153 0298 5815

伦理委员会联系人邮箱:

Contact email of the ethic committee:

517493974@qq.com

研究实施负责(组长)单位:

广州中医药大学深圳医院(福田)

Primary sponsor:

Shenzhen Hospital (futian) of Guangzhou University of Chinese Medicine

研究实施负责(组长)单位地址:

广东省深圳市福田区北环大道6001号广州中医药大学深圳医院

Primary sponsor's address:

Shenzhen Hospital (futian) of Guangzhou University of Chinese Medicine ShenzhenChina

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

深圳

Country:

China

Province:

Guangdong

City:

Shenzhen

单位(医院):

广州中医药大学深圳医院(福田)

具体地址:

广东省深圳市福田区北环大道6001号广州中医药大学深圳医院住院楼3楼

Institution
hospital:

Shenzhen Hospital (futian) of Guangzhou University of Chinese Medicine

Address:

Shenzhen Hospital (futian) of Guangzhou University of Chinese Medicine

经费或物资来源:

深圳市福田区卫生公益性科研项目

Source(s) of funding:

Shenzhen Futian District Health Public Welfare Scientific Research Project

研究疾病:

脑梗死

研究疾病代码:

Target disease:

Cerebral infarction

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

上肢功能障碍是中风病常见后遗症,严重影响患者正常生活工作质量。课题组前期研究证实针刺结合康复训练在改善中风后肢体功能方面有较好的临床疗效,岐黄针疗法作为专科引进的新技术,在取穴及针具制作上较常规针刺具有明显的创新性。本研究从生物肌电及炎症水平探索其临床疗效及作用机制,特开展如下工作:1)采用临床量表观察岐黄针结合镜像训练对脑梗死后肢体运动功能的影响;2)表面肌电图(sEMG)检测上肢肌群的肌电积分值(iEMG) 客观评价该疗法对肌电信号的影响;3)检测血清炎症因子观察该疗法对机体炎症反应的影响。从多维度探究岐黄针结合镜像疗法改善脑梗死患者运动功能障碍的临床疗效及作用机制。

Objectives of Study:

Upper limb dysfunction is a common sequelae of stroke which seriously affects the normal quality of life and work. The previous research of the research group confirmed that acupuncture combined with rehabilitation training has a good clinical effect in improving limb function after stroke and Qihuang acupuncture therapy as a new technology introduced by the specialty is more innovative than conventional acupuncture in acupoint extraction and needle making. In this study the clinical efficacy and mechanism of action were explored from the level of biological electromyography and inflammation and the following work was carried out: 1) the effect of Qihuang needle combined with mirror training on limb motor function after cerebral infarction was observed by clinical scale; 2) surface electromyography (sEMG) to detect the electromyography (iEMG) of upper limb muscle groups to objectively evaluate the effect of the therapy on EMG signals; 3) Detect serum inflammatory factors to observe the effect of the therapy on the body's inflammatory response. To explore the clinical efficacy and mechanism of Qihuang needle combined with mirror therapy in improving motor dysfunction in patients with cerebral infarction from multiple dimensions.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1: 符合缺血性脑卒中诊断标准者 2: 年龄在35-75岁之间者,男女不限 3: 初次中风患者,发病在2周-6个月 4: 存在上肢功能障碍:临床神经功能缺损程度评分中肢体功能缺损评分累计≥10分 5: 患者意识清醒,生命体征平稳者 6: 运动觉及视觉想象问卷(修订版)测试正常 7: 签署知情同意书者

Inclusion criteria

1: Those who meet the above diagnostic criteria for ischemic stroke 2:Patients with first stroke the onset of stroke is 2 weeks to 3 months 3: Over 40 years old under 75 years old both male and female 4: The cumulative score of limb function deficit in the clinical neurological deficit score (NDS) is greater than or equal to 10 points 5: The patient is conscious and has stable vital signs 6: The kinesthetic and imagery questionnaire (KVIQ) test was normal 7: Those who signed the informed consent form.

排除标准:

1: 有继发性脑出血者 2: 由其他疾病所引起的上肢运动功能障碍,如骨折、肩周炎、脊髓灰质炎、脑寄生虫病、脑肿瘤、心脏病、脑外伤等 3: 有活动性癫痫者 4: 妊娠或哺乳期妇女 5: 不能耐受坐位30分钟训练者 6: 除参与本研究外,还参与其他实验或研究者

Exclusion criteria:

1:Patients with secondary cerebral hemorrhage or infarction 2: Upper limb motor dysfunction caused by other diseases such as fractures frozen shoulder poliomyelitis cerebral parasitic diseases brain tumors heart disease traumatic brain injury etc. 3:Those with active epilepsy 4: pregnant or lactating women 5: Those who cannot tolerate 20 minutes of training in the sitting position 6: In addition to participating in this study those who have also participated in other experiments or researchers

研究实施时间:

Study execute time:

From 2021-08-01

To      2024-07-31

征募观察对象时间:

Recruiting time:

From 2022-11-24

To      2023-06-01

干预措施:

Interventions:

组别:

岐黄针+镜像组

样本量:

35

Group:

Qihuang needle therapy combined with mirror therapy group

Sample size:

干预措施:

岐黄针+镜像疗法

干预措施代码:

Intervention:

Qihuang needle therapy combined with mirror therapy

Intervention code:

组别:

毫针+镜像疗法组

样本量:

35

Group:

acupuncture combined with mirror therapy group

Sample size:

干预措施:

毫针+镜像疗法

干预措施代码:

Intervention:

acupuncture combined with mirror therapy

Intervention code:

组别:

岐黄针组

样本量:

35

Group:

Qihuang needle therapy group

Sample size:

干预措施:

岐黄针

干预措施代码:

Intervention:

Qihuang needle therapy

Intervention code:

样本总量 Total sample size : 105

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东

市(区县):

深圳

Country:

China

Province:

Guangdong

City:

Shenzhen

单位(医院):

广州中医药大学深圳医院(福田)

单位级别:

三甲

Institution/hospital:

Shenzhen Hospital (futian) of Guangzhou University of Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

表面肌电图均方根值(RMS)及中位频率(MF)

指标类型:

主要指标

Outcome:

Surface Electromyograph

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

上肢运动功能

指标类型:

次要指标

Outcome:

Fugl-Meyer assessment-upper extremity FMA-UE

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

结束

Completed

年龄范围:

最小 35
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究采用SPSS25.0软件生成的随机数表,并制成随机分配卡105张,装进按次序编号的不透明信封,卡片编号与信封序号一致。病例患者进入试验前需拆封并严格按照获取信封中的编号及相应的随机数列卡片进行分组及干预。将符合纳入标准的105例患者分3组平行进行,分组为岐黄针+镜像组、岐黄针组、毫针+镜像组,每组各35例。3组病人按1:1:1分配。

Randomization Procedure (please state who generates the random number sequence and by what method):

In this study the random number table generated by SPSS25.0 software was used to make 105 random allocation cards which were loaded into opaque envelopes numbered in order and the card numbers were consistent with the envelope serial numbers. Before entering the trial the patients should be unpacked and the number in the obtained envelope and the corresponding random number series card should be grouped and intervened in strict accordance with the number in the obtained envelope. A total of 105 patients who met the inclusion criteria were divided into three groups divided into Qihuang needle + mirror group Qihuang needle group and millineedle + mirror group with 35 cases in each group. The 3 groups of patients were assigned 1:1:1.

盲法:

单盲(对受试者隐藏分组),对评估者隐藏分组

Blinding:

Single-blind (groups are hidden from subjects) groups are hidden from evaluators

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan临床试验公共管理平台

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan Clinical Trial Management Public Platform

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form CRF

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统